Ma M, Qerqez A, Hill K, Azouz L, Youngblood H, Hill S
PNAS Nexus. 2024; 4(1):pgae556.
PMID: 39726989
PMC: 11670252.
DOI: 10.1093/pnasnexus/pgae556.
Mokhtar H, Zaitone S, El-Sayed K, Lashine R, Ahmed N, Moursi S
Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598348
PMC: 11597433.
DOI: 10.3390/ph17111436.
Zhou X, Zhang F, Zhang X, Zhou D, Zhao Y, Chen B
BMC Med Genomics. 2023; 16(1):280.
PMID: 37940950
PMC: 10634160.
DOI: 10.1186/s12920-023-01698-2.
Chen X, Shi C, He M, Xiong S, Xia X
Signal Transduct Target Ther. 2023; 8(1):352.
PMID: 37709773
PMC: 10502142.
DOI: 10.1038/s41392-023-01570-w.
Saccuzzo E, Youngblood H, Lieberman R
Prog Retin Eye Res. 2023; 95:101188.
PMID: 37217093
PMC: 10330797.
DOI: 10.1016/j.preteyeres.2023.101188.
Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes.
Samant R, Batista S, Larance M, Ozer B, Milton C, Bludau I
Mol Cell Proteomics. 2022; 22(2):100485.
PMID: 36549590
PMC: 9898794.
DOI: 10.1016/j.mcpro.2022.100485.
The biology and inhibition of glucose-regulated protein 94/gp96.
Pugh K, Alnaed M, Brackett C, Blagg B
Med Res Rev. 2022; 42(6):2007-2024.
PMID: 35861260
PMC: 10003671.
DOI: 10.1002/med.21915.
Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins.
Mathieu C, Messaoudi S, Fattal E, Vergnaud-Gauduchon J
Cancer Drug Resist. 2022; 2(3):381-398.
PMID: 35582577
PMC: 8992530.
DOI: 10.20517/cdr.2019.26.
Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms.
McDowell C, Kizhatil K, Elliott M, Overby D, van Batenburg-Sherwood J, Millar J
Invest Ophthalmol Vis Sci. 2022; 63(2):12.
PMID: 35129590
PMC: 8842499.
DOI: 10.1167/iovs.63.2.12.
The heat shock response and small molecule regulators.
Kurop M, Huyen C, Kelly J, Blagg B
Eur J Med Chem. 2021; 226:113846.
PMID: 34563965
PMC: 8608735.
DOI: 10.1016/j.ejmech.2021.113846.
Myocilin-associated Glaucoma: A Historical Perspective and Recent Research Progress.
Sharma R, Grover A
Mol Vis. 2021; 27:480-493.
PMID: 34497454
PMC: 8403517.
Molecular Insights into Myocilin and Its Glaucoma-Causing Misfolded Olfactomedin Domain Variants.
Lieberman R, Ma M
Acc Chem Res. 2021; 54(9):2205-2215.
PMID: 33847483
PMC: 8771271.
DOI: 10.1021/acs.accounts.1c00060.
Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity.
Marcyk P, LeBlanc E, Kuntz D, Xue A, Ortiz F, Trilles R
J Med Chem. 2021; 64(2):1139-1169.
PMID: 33444025
PMC: 8493596.
DOI: 10.1021/acs.jmedchem.0c01777.
Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone.
Yan P, Patel H, Sharma S, Corben A, Wang T, Panchal P
Cell Rep. 2020; 31(13):107840.
PMID: 32610141
PMC: 7372946.
DOI: 10.1016/j.celrep.2020.107840.
Old and New Approaches to Target the Hsp90 Chaperone.
Sanchez J, Carter T, Cohen M, Blagg B
Curr Cancer Drug Targets. 2019; 20(4):253-270.
PMID: 31793427
PMC: 7502213.
DOI: 10.2174/1568009619666191202101330.
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
Mak O, Chand R, Reynisson J, Leung I
Int J Mol Sci. 2019; 20(21).
PMID: 31717777
PMC: 6862331.
DOI: 10.3390/ijms20215333.
Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors.
Huang D, LeBlanc E, Shekhar-Guturja T, Robbins N, Krysan D, Pizarro J
J Med Chem. 2019; 63(5):2139-2180.
PMID: 31513387
PMC: 7069776.
DOI: 10.1021/acs.jmedchem.9b00826.
Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation.
Huard D, Jonke A, Torres M, Lieberman R
Sci Rep. 2019; 9(1):12769.
PMID: 31484937
PMC: 6726633.
DOI: 10.1038/s41598-019-48751-8.
The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer.
Hoter A, Rizk S, Naim H
Cancers (Basel). 2019; 11(8).
PMID: 31426412
PMC: 6721600.
DOI: 10.3390/cancers11081194.
Stable calcium-free myocilin olfactomedin domain variants reveal challenges in differentiating between benign and glaucoma-causing mutations.
Hill S, Kwon M, Martin M, Suntharalingam A, Hazel A, Dickey C
J Biol Chem. 2019; 294(34):12717-12728.
PMID: 31270212
PMC: 6709634.
DOI: 10.1074/jbc.RA119.009419.